| 1 | 1/1 | 返回列表 |
| 查看: 306 | 回復: 0 | |||
[交流]
路易斯安那州立大學(LSU-Shreveport Health Center)Hongyan Guo教授招聘博士后
|
|
postdoctoral fellow position, microbiology&immunology department, dr. hongyan guo lab, lsu-shreveport health center research direction: project 1: the role of cell death in hsv-1 pathogenesis receptor-interacting protein kinase 3 (ripk3) is a central regulator of programmed cell death, activated by upstream molecules such as ripk1, trif, and zbp1. zbp1 acts as an intracellular sensor of z-form nucleic acids and recruits ripk3 to initiate cell death. our research focuses on the zbp1 ligands that activate zbp1, elucidating the mechanisms of zbp1 activation, and determining the downstream effects of this pathway during hsv-1 infection and pathogenesis. these studies aim to define zbp1’s role as a key antiviral sensor and uncover how hsv-1 subverts host cell death pathways to facilitate infection. project 2: targeting necroptosis pathways in tumors using oncolytic hsv-1 oncolytic virotherapy is a promising cancer treatment strategy that employs viruses to selectively infect and destroy tumor cells while sparing normal tissue. hsv-1 is particularly well-suited for this approach due to its broad cellular tropism and amenability to genetic engineering. our research explores how engineered hsv-1 can be used to induce necroptosis—a form of regulated cell death—in cancer cells, thereby enhancing antitumor immune responses. by leveraging synergistic tumor models, we aim to dissect the role of necroptosis in oncolytic virus therapy and contribute to the development of safer, more effective, and highly targeted cancer treatments. mentor information: https://schoolofgradstudies.lsuh ... gy/research/guo-lab publication: https://scholar.google.com/citat ... ;amp;sortby=pubdate funding: nih r21, r01. qualifications: required: 1. ph.d. or m.d. at the time of appointment. 2. research experience in immunology, molecular biology, cancer, virology. preferred experience: 1. strong publication in related field. 2. human-derived ipsc models. 3. structural biochemistry, morphology. compensation and benefits: salary follows nih standard scale, start at $55000 for first year post-doc with extra benefits. apply: interested candidates should email the following documents to dr. hongyan guo (hongyan.guo@lsuhs.edu) with subject line as: postdoc application-name). 1. cover letter describing research experience and interests. 2. cv 3. name and contact information of three references. about lsu health shreveport (lsuhs): lsu health shreveport (lsuhs) is a public university (r1) focused on health sciences education and located in shreveport, louisiana. microbiology and immunology: https://schoolofgradstudies.lsuh ... logy-and-immunology postdoc research: https://schoolofgradstudies.lsuh ... al-fellows/postdocs |
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 266求調劑 +6 | 哇塞王帥 2026-03-03 | 6/300 |
|
|---|---|---|---|---|
|
[考研] 一志愿武漢理工大學-085602-總分296分-求調劑 +3 | 紫川葡柚 2026-03-04 | 3/150 |
|
|
[考研] 求調劑 +3 | 泡了個椒 2026-03-04 | 3/150 |
|
|
[考研] 0856材料與化工,270求調劑 +14 | YXCT 2026-03-01 | 16/800 |
|
|
[考博] 26超級電容器申博 +4 | dhdjdjend 2026-02-25 | 4/200 |
|
|
[考研] 一志愿西工大材料學,英一數(shù)二總分321分,求調劑。 +3 | zz05zz 2026-03-02 | 5/250 |
|
|
[考研] 環(huán)境工程學碩288求助調劑 +7 | 多吃億口芝士 2026-03-02 | 7/350 |
|
|
[基金申請] 請問大家,研究風險與應對措施那里, 大家都怎么寫呢 ? +3 | cauasen 2026-03-02 | 3/150 |
|
|
[考研] 085600材料與化工 298 調劑 +3 | 小西笑嘻嘻 2026-03-03 | 3/150 |
|
|
[基金申請] 沒有青基直接申請面上,感覺自己瘋了 +5 | kevin63t 2026-03-02 | 6/300 |
|
|
[考研] 281電子信息求調劑 +3 | jhtfeybgj 2026-03-02 | 6/300 |
|
|
[考研] 化工335求調劑 +5 | 摸摸貓貓頭 2026-03-02 | 5/250 |
|
|
[考研] 302材料工程求調劑 +5 | Doleres 2026-03-01 | 6/300 |
|
|
[考研] 306分材料調劑 +5 | chuanzhu川燭 2026-03-01 | 6/300 |
|
|
[考研] 一志愿中石油(華東)本科齊魯工業(yè)大學 +3 | 石能偉 2026-03-02 | 3/150 |
|
|
[考研] 材料與化工328求調劑 +3 | 。,。,。,。i 2026-03-02 | 3/150 |
|
|
[考研] 一志愿鄭大材料學碩298分,求調劑 +6 | wsl111 2026-03-01 | 6/300 |
|
|
[基金申請]
|
Doma 2026-03-01 | 7/350 |
|
|
[基金申請]
剛錄用,沒有期刊號,但是在線可看的論文可以放為代表作嗎
10+3
|
arang1 2026-03-01 | 3/150 |
|
|
[考研] 調劑 +3 | 簡木ChuFront 2026-02-28 | 3/150 |
|